Browse Studies — Arctuva

Phase 2

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Par…

IgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy

Estimated

~$10 – $8,750

Akebia TherapeuticsNCT06419205

Phase 3

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is a…

Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06858319

Phase 3

An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic…

C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT03955445

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened …

Chronic Kidney DiseaseGlomerulopathy

Estimated

~$10 – $750

University of MichiganNCT01016613

A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in C3 Glomerulopathy (C3G) in the US

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced b…

C3 Glomerulopathy

Estimated

~$10 – $1,050

Novartis PharmaceuticalsNCT07029542